S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NYSE:NVTA

Invitae News Headlines

$52.59
-0.85 (-1.59 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$52.53
Now: $52.59
$56.16
50-Day Range
$41.81
MA: $49.24
$57.40
52-Week Range
$7.41
Now: $52.59
$61.59
Volume237,090 shs
Average Volume4.70 million shs
Market Capitalization$9.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.11

Headlines

Invitae (NYSE NVTA) News Headlines Today

Source:
SourceHeadline
3 Groundbreaking Genomics Stocks to Buy Now (NVTA)3 Groundbreaking Genomics Stocks to Buy Now (NVTA)
marketbeat.com - January 8 at 6:58 PM
Invitae (NYSE:NVTA) Stock Rating Lowered by BidaskClubInvitae (NYSE:NVTA) Stock Rating Lowered by BidaskClub
marketbeat.com - December 16 at 7:33 AM
Invitae (NYSE:NVTA) Rating Increased to Hold at Zacks Investment ResearchInvitae (NYSE:NVTA) Rating Increased to Hold at Zacks Investment Research
marketbeat.com - November 18 at 5:20 AM
Zacks Investment Research Downgrades InVitae (NYSE:NVTA) to HoldZacks Investment Research Downgrades InVitae (NYSE:NVTA) to Hold
marketbeat.com - October 16 at 5:26 AM
InVitae (NYSE:NVTA) Coverage Initiated at Morgan StanleyInVitae (NYSE:NVTA) Coverage Initiated at Morgan Stanley
marketbeat.com - September 9 at 7:11 AM
InVitae (NYSE:NVTA) Price Target Raised to $37.25InVitae (NYSE:NVTA) Price Target Raised to $37.25
marketbeat.com - August 5 at 8:37 AM
Invitae teams up with healthcare giants to develop MRD detection panel - Seeking AlphaInvitae teams up with healthcare giants to develop MRD detection panel - Seeking Alpha
seekingalpha.com - January 14 at 8:55 PM
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) - PRNewswireLeading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) - PRNewswire
prnewswire.com - January 14 at 8:55 PM
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
finance.yahoo.com - January 14 at 8:55 PM
Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform - GlobeNewswirePacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform - GlobeNewswire
globenewswire.com - January 13 at 10:31 PM
Invitae (NYSE:NVTA) Stock Price Up 7.9%Invitae (NYSE:NVTA) Stock Price Up 7.9%
americanbankingnews.com - January 13 at 9:41 PM
Why Invitae Stock Flew Higher Today - Motley FoolWhy Invitae Stock Flew Higher Today - Motley Fool
fool.com - January 13 at 5:31 PM
Why Is It Moving? Looking At Invitaes Price Action Today - BenzingaWhy Is It Moving? Looking At Invitae's Price Action Today - Benzinga
benzinga.com - January 13 at 12:30 PM
Concert Genetics Launches Preferred Laboratory Network - PRNewswireConcert Genetics Launches Preferred Laboratory Network - PRNewswire
prnewswire.com - January 13 at 7:29 AM
News Flash: 8 Analysts Think Invitae Corporation (NYSE:NVTA) Earnings Are Under Threat - Yahoo FinanceNews Flash: 8 Analysts Think Invitae Corporation (NYSE:NVTA) Earnings Are Under Threat - Yahoo Finance
finance.yahoo.com - January 13 at 7:29 AM
News Flash: 8 Analysts Think Invitae Corporation (NYSE:NVTA) Earnings Are Under ThreatNews Flash: 8 Analysts Think Invitae Corporation (NYSE:NVTA) Earnings Are Under Threat
finance.yahoo.com - January 13 at 7:29 AM
These 3 Big 2020 Stock Market Winners Took Big Hits Monday - Motley FoolThese 3 Big 2020 Stock Market Winners Took Big Hits Monday - Motley Fool
fool.com - January 12 at 8:32 AM
Notable Monday Option Activity: NVTA, ATSG, KTBNotable Monday Option Activity: NVTA, ATSG, KTB
nasdaq.com - January 12 at 3:31 AM
Invitae (NYSE:NVTA) Stock Price Down 10.2%Invitae (NYSE:NVTA) Stock Price Down 10.2%
americanbankingnews.com - January 11 at 9:16 PM
Looking Into Invitaes Return On Capital Employed - Yahoo FinanceLooking Into Invitae's Return On Capital Employed - Yahoo Finance
finance.yahoo.com - January 11 at 5:20 PM
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume - Yahoo FinanceInvitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume - Yahoo Finance
finance.yahoo.com - January 11 at 5:20 PM
Looking Into Invitaes Return On Capital EmployedLooking Into Invitae's Return On Capital Employed
benzinga.com - January 11 at 12:18 PM
A new JPM: Biotechs big meeting week goes virtual with swag and questions - San Francisco Business TimesA new JPM: Biotech's big meeting week goes virtual with swag and questions - San Francisco Business Times
bizjournals.com - January 8 at 3:05 PM
NVTA Crosses Above Average Analyst Target - NasdaqNVTA Crosses Above Average Analyst Target - Nasdaq
nasdaq.com - January 8 at 3:05 PM
Invitae (NYSE:NVTA) Trading 5.9% Higher Invitae (NYSE:NVTA) Trading 5.9% Higher
americanbankingnews.com - January 5 at 9:18 PM
We Found a Bubble—but It May Not Be What You Think It IsWe Found a Bubble—but It May Not Be What You Think It Is
finance.yahoo.com - January 1 at 1:14 PM
We Found a Bubble–but It May Not Be What You Think It IsWe Found a Bubble–but It May Not Be What You Think It Is
finance.yahoo.com - December 31 at 7:21 PM
Invitae (NYSE:NVTA) Trading Down 5.4%Invitae (NYSE:NVTA) Trading Down 5.4%
americanbankingnews.com - December 31 at 7:14 PM
Colorado biotech firms raised a combined $2.6 billion in 2020 - Denver Business JournalColorado biotech firms raised a combined $2.6 billion in 2020 - Denver Business Journal
bizjournals.com - December 31 at 12:01 AM
Invitae to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo FinanceInvitae to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
finance.yahoo.com - December 29 at 7:58 AM
Jason W. Myers Sells 48,971 Shares of Invitae Co. (NYSE:NVTA) StockJason W. Myers Sells 48,971 Shares of Invitae Co. (NYSE:NVTA) Stock
americanbankingnews.com - December 29 at 5:44 AM
Are Genomic Stocks Are The Next FANG Stocks? - Yahoo FinanceAre Genomic Stocks Are The Next FANG Stocks? - Yahoo Finance
finance.yahoo.com - December 24 at 1:48 PM
Best Biotech Stocks to Buy for 2021 - TheStreetBest Biotech Stocks to Buy for 2021 - TheStreet
thestreet.com - December 24 at 1:48 PM
Are Genomic Stocks Are The Next FANG Stocks? - BenzingaAre Genomic Stocks Are The Next FANG Stocks? - Benzinga
benzinga.com - December 24 at 8:48 AM
The Top Five Hypergrowth Industries Im Targeting In 2021 - ForbesThe Top Five Hypergrowth Industries I'm Targeting In 2021 - Forbes
forbes.com - December 23 at 12:12 PM
Global Prenatal Testing and Newborn Screening Market Report 2020-2030: COVID-19 Growth and Change - Market to Recover in 2023 to Reach $6.04 Bn after a -4.79% Decline in 2020 - Yahoo FinanceGlobal Prenatal Testing and Newborn Screening Market Report 2020-2030: COVID-19 Growth and Change - Market to Recover in 2023 to Reach $6.04 Bn after a -4.79% Decline in 2020 - Yahoo Finance
finance.yahoo.com - December 22 at 5:29 AM
Editas surges 50% as ARK founder Cathie Wood sees genomic stocks driving returns for the next 5 years - Business InsiderEditas surges 50% as ARK founder Cathie Wood sees genomic stocks driving returns for the next 5 years - Business Insider
businessinsider.com - December 21 at 5:41 PM
Invitae: Network Strategy And Industry Tailwinds Should Offer Path To Profitability - Seeking AlphaInvitae: Network Strategy And Industry Tailwinds Should Offer Path To Profitability - Seeking Alpha
seekingalpha.com - December 21 at 7:39 AM
Is BJ Stock Buy Or Sell? - Yahoo FinanceIs BJ Stock Buy Or Sell? - Yahoo Finance
finance.yahoo.com - December 20 at 7:56 PM
Invitae Corp (NVTA) COO Kenneth D. Knight Sold $680,901 of Shares - Yahoo FinanceInvitae Corp (NVTA) COO Kenneth D. Knight Sold $680,901 of Shares - Yahoo Finance
finance.yahoo.com - December 19 at 1:37 AM
Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster - PRNewswireInvitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster - PRNewswire
prnewswire.com - December 17 at 6:19 PM
Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster - Yahoo FinanceInvitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster - Yahoo Finance
finance.yahoo.com - December 17 at 1:18 PM
Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses FasterInvitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster
finance.yahoo.com - December 17 at 8:17 AM
Colorados Life Sciences Ecosystem Raises $1.2 Billion in 2020 - Business WireColorado's Life Sciences Ecosystem Raises $1.2 Billion in 2020 - Business Wire
businesswire.com - December 15 at 2:07 PM
Genomics testing provider ArcherDX officially withdraws $100 million IPO following acquisition by Invitae - NasdaqGenomics testing provider ArcherDX officially withdraws $100 million IPO following acquisition by Invitae - Nasdaq
nasdaq.com - December 14 at 11:04 PM
Notable Friday Option Activity: VIAC, NVTA, NVAXNotable Friday Option Activity: VIAC, NVTA, NVAX
nasdaq.com - December 12 at 10:24 AM
Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium - PRNewswireInvitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium - PRNewswire
prnewswire.com - December 9 at 8:28 AM
Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer SymposiumInvitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium
finance.yahoo.com - December 9 at 8:28 AM
Stock Alert: Invitae Corporation Touches New High - NasdaqStock Alert: Invitae Corporation Touches New High - Nasdaq
nasdaq.com - December 7 at 5:03 PM
New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients - PRNewswireNew Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients - PRNewswire
prnewswire.com - November 19 at 6:05 PM
New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer PatientsNew Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients
finance.yahoo.com - November 19 at 1:05 PM
Imagine Holding Invitae (NYSE:NVTA) Shares While The Price Zoomed 557% Higher - Yahoo FinanceImagine Holding Invitae (NYSE:NVTA) Shares While The Price Zoomed 557% Higher - Yahoo Finance
finance.yahoo.com - November 11 at 12:40 AM
Imagine Holding Invitae (NYSE:NVTA) Shares While The Price Zoomed 557% HigherImagine Holding Invitae (NYSE:NVTA) Shares While The Price Zoomed 557% Higher
finance.yahoo.com - November 10 at 12:38 PM
Invitae: Growth With Massive DilutionInvitae: Growth With Massive Dilution
seekingalpha.com - November 9 at 8:21 PM
Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1 - GlobeNewswirePassage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1 - GlobeNewswire
globenewswire.com - November 9 at 10:20 AM
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020 - Yahoo FinanceInvitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020 - Yahoo Finance
finance.yahoo.com - November 7 at 7:53 PM
This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.